Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1569912 dose-finding trial in major depressive disorder
jRCT2061240061Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Randomised, double-blind trial of BI 1569912 in major depressive disorder (MDD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in Montgomery-Asberg Depression Rating Scale total score at Week 6. Started Nov 2024; status: completed.
02
Drugs
BI 1569912
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2061240061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240061.